publication venue for
- Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials. 498-506. 2020
- Low-Level Viremia Is Associated With Clinical Progression in HIV-Infected Patients Receiving Antiretroviral Treatment.. 329-337. 2018
- Contribution of Oxidative Stress to Non-AIDS Events in HIV-Infected Patients. 36-44. 2017
- Implementation and Operational Research: Barriers and Facilitators to Combined ART Initiation in Pregnant Women With HIV: Lessons Learnt From a PMTCT B+ Pilot Program in Swaziland. 24-30. 2015
- Shorter telomere length predicts poorer immunological recovery in virologically suppressed HIV-1-infected patients treated with combined antiretroviral therapy. 21-29. 2015
- Low-level HIV viremia is associated with microbial translocation and inflammation.. 129-134. 2013
- Highly sensitive and specific model for predicting HIV-1 tropism in treatment-experienced patients combining interpretation of V3 loop sequences and clinical parameters.. 51-58. 2011
- A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression. 290-297. 2009
- Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. . 29-36. 2009
- Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy.. 422-428. 2008
- Low prevalence of peripheral arterial disease in HIV-infected patients with multiple cardiovascular risk factors.. 126-127. 2008
- Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters.. 241-244. 2008
- Prevalence of peripheral arterial disease in HIV-infected patients with multiple cardiovascular risk factors.. 126-127. 2008
- Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors. 167-173. 2007
- Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral experienced HIV-1 infected patients (CAL30001 Study). 598-606. 2006
- Highly Active Antiretroviral Therapy Interruption: Predictors and Virologic and Immunologic Consequences. 554-551. 2006
- Osteonecrosis in patients infected with HIV: clinical epidemiology and natural history in a large case series from Spain.. 286-292. 2006
- Trends in AIDS and Mortality in HIV-Infected Subjects With Hemophilia From 1985 to 2003. 624-631. 2006
- Trends in AIDS and Mortality in HIV-Infected Subjects With Hemophilia From 1985 to 2003: The Competing Risks for Death Between AIDS and Liver Disease. 624-631. 2006
- Prevalence and factors associated with transmitted HIV drug resistance: the role of patient characteristics and different interpretation algorithm. 505-511. 2005
- Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. . 417-425. 2005
- Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and Didanosine?. 427-428. 2004
- Lipid Abnormalities in HIV-Infected Patients and Lopinavir Plasma Concentrations. 1107-1109. 2004
- Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion. 76-83. 2003
- Impact of tuberculosis on HIV disease progression in persons with well-documented time of HIV seroconversion. 184-190. 2003
- Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens . 594-600. 2003
- Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters. 303-310. 2003
- Trends in incidence and prevalence of HIV-1 infection in intravenous drug users. 297-301. 1995